ESMO 2023 GI Cancer Highlights – Codebreak300, CABINET, GASTFOX

In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff:

- Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer

- CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus

- GASTFOX – Evaluate FOLFOX With or Without Docetaxel (TFOX) as First Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma